Wellington Partners has held a first closing for Wellington Partners IV Life Science on €70m.
Investors Wellcome Trust, Novator Partners, Stefnir and General Catalyst participate in the round
GP reportedly buys a 70% stake in the business, valued at €30.5m
Omers Ventures associate director Bryony Marshall will join the board of the company
Paul Tilt catches up with the CEO of the fully diversified impact fund, to discuss the latest trends, hurdles and outlook for the strategy